Akili, Inc. announced that EndeavorOTC, the mobile video game treatment clinically proven to improve attention and focus in adults with ADHD, is now available on Google Play for popular Android devices, including most Samsung Galaxy and Google Pixel models. Out of the estimated 11 million adults living with ADHD in the United States, approximately 40% are Android users so the company believes this release represents a crucial step in offering an accessible non-drug treatment option to adults with ADHD, particularly amid the continued stimulant medication shortage and ongoing mental health crisis. EndeavorOTC is built on the same technology as Akili?s EndeavorRx®, the world?s first and only FDA-authorized video game treatment, for children 8-12 years old with ADHD.

In a recent clinical trial, EndeavorOTC significantly improved focus, attention, and overall quality of life in adults struggling with ADHD symptoms. On average, participants? ability to focus improved by 85%; over one-third of participants no longer exhibited an attention deficit following treatment, and 73% of participants reported quality of life improvements. The release of EndeavorOTC comes at a time when the ADHD community faces continued challenges accessing care.

Fueled by manufacturing issues and record-high prescription rates, the stimulant shortage continues and now affects multiple ADHD drugs. Last month, the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) issued a joint statement on the ongoing nationwide shortage of stimulants for the treatment of conditions such as ADHD, noting the FDA?s support of non-drug treatment options including Akili?s EndeavorRx product. The Android release follows EndeavorOTC?s release on the Apple iOS App Store® in June 2023.

EndeavorOTC now features Akili?s recently released Focus Score, a new metric for users. Focus Score provides a measurement of how quickly and accurately patients can complete a task despite distractions during gameplay, assisting with setting benchmarks and quantifying progress. A patient?s personalized baseline Focus Score is calculated during treatment onboarding, along with a target Focus Score that serves as a treatment goal.

In Akili?s recent adult ADHD clinical trial, Focus Score improvements were directly related to improvement in ADHD-related symptoms and overall quality of life?things like being able to complete tasks or keep track of important items like wallet and keys.